| Unique ID issued by UMIN | UMIN000063637 |
|---|---|
| Receipt number | R000072744 |
| Scientific Title | Outcomes of T2DM Outpatients: Medical AI Optimization (O-TOMO): A Randomized Controlled Trial |
| Date of disclosure of the study information | 2026/11/16 |
| Last modified on | 2026/11/16 09:18:25 |
Evaluation of the Effectiveness of AI-Based Health Support for Patients with Type 2 Diabetes
Evaluation of the Effectiveness of AI-Based Health Support for Patients with Type 2 Diabetes
Outcomes of T2DM Outpatients: Medical AI Optimization (O-TOMO): A Randomized Controlled Trial
Outcomes of T2DM Outpatients: Medical AI Optimization (O-TOMO): A Randomized Controlled Trial
| Japan |
Type 2 diabetes mellitus (T2DM)
| Endocrinology and Metabolism |
Others
NO
To evaluate the impact of an artificial intelligence (AI)-driven health support tool (O-TOMO) on self-care indicators in patients with type 2 diabetes.
Efficacy
Not applicable
The change in the Summary of Diabetes Self-Care Activities (J-SDSCA) score from baseline to the third outpatient visit in the intervention group compared with the control group.
Secondary Endpoint 1:
Change in the mean total score obtained from the PAM-13 (Patient Activation Measure) or alternative scales evaluating self-efficacy and empowerment (e.g., PEPPI-10, J-SEMCD-6, CHAI) before and after the first visit, as well as from the first visit to the third outpatient visit.
Secondary Endpoint 2:
Mean or aggregate score of the safety and accuracy of AI-generated summaries based on clinical experts' evaluation.
Secondary Endpoint 3:
Responses (feedback) obtained from semi-structured interviews exploring healthcare providers' and patients' experiences with O-TOMO.
Secondary Endpoint 4:
Evaluation of treatment plan adherence rate based on a patient questionnaire (compliance survey regarding treatment plans, clinic visits, etc., e.g., presence or absence of appointment reschedules/cancellations).
Exploratory Endpoint 1:
Change in HbA1c from baseline to the third outpatient visit, compared with the control group.
Exploratory Endpoint 2:
Change in total scores or other metrics obtained from caregiver questionnaire responses using either the BIC-11 (Burden Index of Caregiver) or the CRA-J-10 (Caregiver Reaction Assessment Japanese version 10 items).
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
No treatment
2
Treatment
| Other |
Use of the Smartphone Application (O-TOMO) Over Three Outpatient Visits (3-4 Month Period)
Usual Outpatient Care (Control Group)
| 18 | years-old | <= |
| Not applicable |
Male and Female
Patients:
1. Age: Adults (18 years of age or older)
2. Scheduled Visit: Must have a scheduled appointment with a primary care/attending physician at our hospital in one of the outpatient clinics participating in this study.
3. Treatment & Follow-up Expectation: Must have scheduled appointments for the continuous management of type 2 diabetes and be expected to complete 3 outpatient visits within the 3-to-4-month study period.
4. Language Ability: Must be able to read and write Japanese.
5. Internet Access: Must have access to Wi-Fi or the Internet.
Caregivers:
1. Age: Adults (18 years of age or older)
2. Role: Family members or equivalent individuals providing care for the patient (study participant).
Patients:
1. Emergency Medical Condition: Conditions requiring emergency medical care.
2. Pregnancy: Currently pregnant (based on self-report or medical records).
3. Other Disqualifying Conditions: Any other medical condition or reason that, in the judgment of the Principal Investigator or Sub-Investigator, may interfere with study participation, study procedures, or data collection.
4. Prior Participation: Individuals who have previously participated in this study.
5. Lack of Caregiver Consent: Patients requiring assistance or accompaniment from family members or caregivers for daily self-care or clinic visits, for whom consent to participate in this study cannot be obtained from the respective family member or caregiver.
Caregivers:
1. Difficulty Providing Support: Individuals with difficulty reading or writing Japanese, or any condition making it difficult to support the patient's use of the O-TOMO tool.
2: Prior Participation: Individuals who have previously participated in this study.
124
| 1st name | Yuichiro |
| Middle name | |
| Last name | Yano |
Juntendo University
Department of General Medicine
113-8421
2-1-1 Hongo, Bunkyo-ku, Tokyo
+81-3-3813-3111
y.yano@juntendo.ac.jp
| 1st name | Yuichiro |
| Middle name | |
| Last name | Yano |
Juntendo University
Department of General Medicine
113-8421
2-1-1 Hongo, Bunkyo-ku, Tokyo
+81-3-3813-3111
y.yano@juntendo.ac.jp
Juntendo University
Google LLC
Profit organization
Research Ethics Committee, Faculty of Medicine, Juntendo University
3-1-3 Hongo, Bunkyo-ku, Tokyo
03-3814-5672
hongo-rinri@juntendo.ac.jp
NO
| 2026 | Year | 11 | Month | 16 | Day |
Unpublished
Preinitiation
| 2026 | Year | 11 | Month | 06 | Day |
| 2027 | Year | 11 | Month | 06 | Day |
| 2026 | Year | 12 | Month | 04 | Day |
| 2027 | Year | 05 | Month | 31 | Day |
| 2026 | Year | 11 | Month | 16 | Day |
| 2026 | Year | 11 | Month | 16 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072744